Key terms
About FATE
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest FATE news
Mar 28
7:42am ET
Fate Therapeutics price target raised to $6 from $2 at BofA
Mar 28
4:58am ET
Cautious Outlook on Fate Therapeutics: Sell Rating Maintained Amid Competitive and Validation Concerns
Mar 25
9:10pm ET
Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE) and AbbVie (ABBV)
Mar 19
8:46am ET
Fate Therapeutics prices 14.5M shares at $5.50 in underwritten offering
Mar 19
6:28am ET
Fate Therapeutics: A Hold Rating Amidst Financial Uncertainty and Clinical Milestones
Mar 01
1:09am ET
Fate Therapeutics: Buy Rating Affirmed Amid Promising Pipeline and Upcoming Oncology Catalysts
Feb 27
11:57pm ET
Fate Therapeutics: Hold Rating Maintained Amid Anticipation of Pivotal Clinical Data
Feb 27
8:26am ET
Fate Therapeutics price target lowered to $11 from $13 at Canaccord
Feb 27
8:15am ET
Fate Therapeutics price target raised to $7 from $3 at Wedbush
Feb 27
7:49am ET
Oppenheimer Reaffirms Their Hold Rating on Fate Therapeutics (FATE)
Feb 27
7:26am ET
Market Perform: A Cautious Outlook on Fate Therapeutics’ Clinical Progress and Immunology Prospects
Feb 27
6:30am ET
Fate Therapeutics: A Cautious Hold Amidst Upcoming Clinical Milestones and Improved Financial Health
Feb 27
5:50am ET
Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE), BioCryst (BCRX) and Veeva Systems (VEEV)
Feb 27
5:30am ET
Fate Therapeutics price target raised to $10 from $6 at Barclays
Feb 27
3:30am ET
Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE), Elanco Animal Health (ELAN) and R1 RCM (RCM)
Feb 26
7:45pm ET
TD Cowen Keeps Their Hold Rating on Fate Therapeutics (FATE)
Feb 26
4:04pm ET
Fate Therapeutics reports Q4 EPS (45c), consensus (52c)
Feb 01
11:24am ET
Biotech Alert: Searches spiking for these stocks today
Jan 31
10:56am ET
Biotech Alert: Searches spiking for these stocks today
Jan 08
8:14am ET
Fate Therapeutics announces initiation of Phase 1 trial of FT825/ONO-8250
No recent news articles are available for FATE
FATE Financials
Key terms
Ad Feedback
FATE Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
FATE Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
